Cystic fibrosis bone disease: Pathophysiology, assessment and prognostic implications

Abeer Anabtawi; Trang Le; Melissa Putman; Vin Tangpricha; Maria Luisa Bianchi

doi:10.1016/j.jcf.2019.08.018

Cystic fibrosis bone disease: Pathophysiology, assessment and prognostic implications

J Cyst Fibros. 2019 Oct:18 Suppl 2:S48-S55. doi: 10.1016/j.jcf.2019.08.018.

Authors

Abeer Anabtawi¹, Trang Le², Melissa Putman³, Vin Tangpricha⁴, Maria Luisa Bianchi⁵

Affiliations

¹ Department of Internal Medicine, Division of Endocrinology, Diabetes and Metabolism, University of Kansas Medical Center, Kansas City, KS, USA. Electronic address: aanabtawi@kumc.edu.
² Departments of Internal Medicine and Pediatrics, Division of Endocrinology, Virginia Commonwealth University, Richmond, VA, USA.
³ Divisions of Endocrinology, Boston Children's Hospital and Massachusetts General Hospital, Boston, MA, USA.
⁴ Division of Endocrinology, Metabolism, & Lipids, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA; The Atlanta VA Medical Center, Decatur, GA, USA.
⁵ Experimental Laboratory for Children's Bone Metabolism Research, Istituto Auxologico Italiano IRCCS, Milano, Italy.

PMID: 31679729
DOI: 10.1016/j.jcf.2019.08.018

Abstract

Cystic fibrosis bone disease (CFBD) is a common long-term complication of cystic fibrosis (CF) that can lead to increased fractures and significant morbidity and mortality in this patient population. CFBD pathophysiology remains poorly understood and is likely to be multifactorial. There are limited studies evaluating diagnostic tools and tests to guide therapeutic decisions and monitoring of CFBD. This review will present and discuss the current evidence.

Keywords: Bone turn over markers; Cystic fibrosis; Cystic fibrosis bone disease; DXA.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Bone Diseases / diagnosis
Bone Diseases / etiology*
Bone Diseases / physiopathology
Cystic Fibrosis / complications*
Humans
Prognosis